Biomarker and pharmacodynamic activity of the transforming growth factor‐beta (TGFβ) inhibitor SAR439459 as monotherapy and in combination with cemiplimab in a phase I clinical study in patients with advanced solid tumors

• Автори: Debbie Robbrecht (Автор), Jean‐Jacques Grob (Автор), Oliver Bechter (Автор), Matteo Simonelli (Автор), Bernard Doger (Автор), Ivan Borbath (Автор), Marcus O. Butler (Автор), Tina Cheng (Автор), Patricia Martin Romano (Автор), Elvire Pons‐Tostivint (Автор), Massimo Di Nicola (Автор), Giuseppe Curigliano (Автор), Min‐Hee Ryu (Автор), Alejo Rodriguez‐Vida (Автор), Dirk Schadendorf (Автор), Elena Garralda (Автор), Giovanni Abbadessa (Автор), Brigitte Demers (Автор), Amele Amrate (Автор), Hong Wang (Автор), Joon Sang Lee (Автор), Robert Pomponio (Автор), Rui Wang (Автор)
• Формат: Книга
• Опубліковано: Wiley, 2024-02-01T00:00:00Z.
• Предмети: article
• Онлайн доступ: Connect to this object online.

Abstract SAR439459, a 'second‐generation' human anti‐transforming growth factor‐beta (TGFβ) monoclonal antibody, inhibits all TGFβ isoforms and improves the antitumor activity of anti‐programmed cell death protein‐1 therapeutics. This study reports the pharmacodynamics (PD) and biomarker r...